These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24049109)

  • 1. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.
    El-Kamary SS; Cohen MB; Bourgeois AL; Van De Verg L; Bauers N; Reymann M; Pasetti MF; Chen WH
    Clin Vaccine Immunol; 2013 Nov; 20(11):1764-70. PubMed ID: 24049109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
    Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
    Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
    Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
    Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
    Lundgren A; Leach S; Tobias J; Carlin N; Gustafsson B; Jertborn M; Bourgeois L; Walker R; Holmgren J; Svennerholm AM
    Vaccine; 2013 Feb; 31(8):1163-70. PubMed ID: 23306362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
    Sukwa N; Mubanga C; Hatyoka LM; Chilyabanyama ON; Chibuye M; Mundia S; Munyinda M; Kamuti E; Siyambango M; Badiozzaman S; Bosomprah S; Carlin N; Kaim J; Sjöstrand B; Simuyandi M; Chilengi R; Svennerholm AM
    Vaccine; 2023 Nov; 41(46):6884-6894. PubMed ID: 37838479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
    Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
    Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin.
    Luo Q; Vickers TJ; Fleckenstein JM
    Clin Vaccine Immunol; 2016 Jul; 23(7):628-37. PubMed ID: 27226279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
    Akhtar M; Chowdhury MI; Bhuiyan TR; Kaim J; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Begum YA; Sharif MZ; Islam LN; Carlin N; Maier N; Fix A; Wierzba TF; Walker RI; Bourgeois AL; Svennerholm AM; Qadri F; Lundgren A
    Vaccine; 2019 Sep; 37(37):5645-5656. PubMed ID: 30473185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.
    Maciel M; Bauer D; Baudier RL; Bitoun J; Clements JD; Poole ST; Smith MA; Kaminski RW; Savarino SJ; Norton EB
    Infect Immun; 2019 Nov; 87(11):. PubMed ID: 31427449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine.
    Jones FR; Hall ER; Tribble D; Savarino SJ; Cassels FJ; Porter C; Meza R; Nunez G; Espinoza N; Salazar M; Luckett R; Scott D
    Vaccine; 2006 May; 24(18):3786-92. PubMed ID: 16343702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.
    Katz DE; DeLorimier AJ; Wolf MK; Hall ER; Cassels FJ; van Hamont JE; Newcomer RL; Davachi MA; Taylor DN; McQueen CE
    Vaccine; 2003 Jan; 21(5-6):341-6. PubMed ID: 12531630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.
    McKenzie R; Bourgeois AL; Frech SA; Flyer DC; Bloom A; Kazempour K; Glenn GM
    Vaccine; 2007 May; 25(18):3684-91. PubMed ID: 17313998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli.
    Lee T; Gutiérrez RL; Maciel M; Poole S; Testa KJ; Trop S; Duplessis C; Lane A; Riddle MS; Hamer M; Alcala A; Prouty M; Maier N; Erdem R; Louis Bourgeois A; Porter CK
    Vaccine; 2021 Sep; 39(39):5548-5556. PubMed ID: 34419306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
    Byrd W; Boedeker EC
    Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
    McKenzie R; Bourgeois AL; Engstrom F; Hall E; Chang HS; Gomes JG; Kyle JL; Cassels F; Turner AK; Randall R; Darsley M; Lee C; Bedford P; Shimko J; Sack DA
    Infect Immun; 2006 Feb; 74(2):994-1000. PubMed ID: 16428745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTa
    Nandre RM; Duan Q; Wang Y; Zhang W
    Vaccine; 2017 Jan; 35(4):552-556. PubMed ID: 28017433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
    Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
    Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
    Lapa JA; Sincock SA; Ananthakrishnan M; Porter CK; Cassels FJ; Brinkley C; Hall ER; van Hamont J; Gramling JD; Carpenter CM; Baqar S; Tribble DR
    Clin Vaccine Immunol; 2008 Aug; 15(8):1222-8. PubMed ID: 18579693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.
    Güereña-Burgueño F; Hall ER; Taylor DN; Cassels FJ; Scott DA; Wolf MK; Roberts ZJ; Nesterova GV; Alving CR; Glenn GM
    Infect Immun; 2002 Apr; 70(4):1874-80. PubMed ID: 11895950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.